Ann: Appendix 4C - Quarterly, page-8

The fact that bot is fully funded to progress two products through to phase 2 completion is excellent.......I'm liking the R&D spend vs. other costs here.......value drivers are numerous........unfortunately not reflected in current mcap.

End of Q1 next yr should see some results for Phase 1b BTX 1308 psoriasis patient studies........

Serious 'dark horse' possibilities exist.........in particular I'm excited about seeing some additional swift progress on the BTX 1801 side of things:

"The pre-clinical testing showed that BTX 1801 was very effective at killing methicillin-resistant staphylococcus aureus strains of bacteria when compared to Permetrex™ or cannabidiol alone".

"The synergistic response observed demonstrates the potential for BTX 1801 to treat both acute and chronic skin infections.This coupled with the inherent anti-inflammatory properties of cannabidiol may elevate BTX 1801 to be the antimicrobial of choice for the treatment of skin infections".

I still can't really fathom it.........that bot is the only company currently working on clinical trials for CBD and its application in the dermatology space...........